---
title: "Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278774326.md"
description: "Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC."
datetime: "2026-03-11T20:11:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278774326.md)
  - [en](https://longbridge.com/en/news/278774326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278774326.md)
generator: "portal-rs"
---

# Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Foghorn Therapeutics Q2 FY26 net loss narrows to $7.2 million; collaboration revenue rises to $16.1 million](https://longbridge.com/en/news/295098647.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**